Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform www.cell.com/cell-report...
22.06.2025 14:15 — 👍 5 🔁 1 💬 0 📌 0
Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform www.cell.com/cell-report...
22.06.2025 14:15 — 👍 5 🔁 1 💬 0 📌 0
A must read for today's afternoon presented today at #AACR25 by C. Curtis: beatiful through work on classical breast cancer subtypes characterization shows deep similarity between HER2+ and ER+ high risk www.nature.com/articles/s41...
30.04.2025 15:41 — 👍 3 🔁 2 💬 0 📌 0Closing plenary session with deeply interesting work presented by C. Curtis and @marleenkok.bsky.social on mTNBC and biomarkers of response to IO: published, almost and ongoing work
30.04.2025 15:36 — 👍 2 🔁 0 💬 0 📌 0At yesterday's opening ceremony, we asked the cancer community to stand together to make their voices heard in support of innovative cancer science and medicine. #CancerResearchSavesLives® #AACR25
28.04.2025 16:33 — 👍 50 🔁 25 💬 1 📌 1Ingenious strategies by Igne Svane to improve TIL therapy activity based on optimization of antigen recognition: tumor cell reprogramming into DC-like, expansion from tumor fragments #AACR25
28.04.2025 22:29 — 👍 1 🔁 0 💬 0 📌 0
Great talk on CAR NK potential by Katy Rezvani: potent citotoxicity, unexpected durable response. Amazing clinical trial pipeline at @mdanderson.bsky.social
28.04.2025 17:59 — 👍 2 🔁 0 💬 0 📌 0
Great work on CAR-T improvement by Marcela Maus: beyond IFNg KO, CRISPR screening libraries in vivo and in vitro to look for the best candidates #AACR25
28.04.2025 13:50 — 👍 2 🔁 0 💬 0 📌 0
Happy to be at #AACR25! Looking forward to witnessing new advances in #Immunotherapy and #CellTherapy 🧬🔬
27.04.2025 15:24 — 👍 2 🔁 1 💬 0 📌 0
Encouraging pre-clinical results for GBM patients: triple-comb (DXM + antiCSF1 + antiTGFB) inhibitis post RT scarring, a niche for tumor recurrence @johannajoyce.bsky.social #AACR25
27.04.2025 16:19 — 👍 2 🔁 0 💬 0 📌 0Second plenary, continuing with genomics. ecDNA old but kind of new for oncologists, relevant clinical implications: resistance to targeted therapies, worse prognosis, immune supressive TME relationship @paulmischel.bsky.social #AACR
27.04.2025 15:50 — 👍 0 🔁 0 💬 0 📌 0
Kickoff talk of first plenary session on genomic evolution, impressive work: from non tumoral to pre-malignant stages by @imartincorena.bsky.social Bioinformatics opening of #AACR25
27.04.2025 14:01 — 👍 4 🔁 0 💬 0 📌 0
A way to start with @bsky.app ! 7 days of cutting edge cancer research #AACR25
27.04.2025 03:31 — 👍 3 🔁 0 💬 0 📌 0